Fast listing for GSK's Aussie drug

Posted 1 April 2025 AM

An Australian-developed cancer drug has hit the PBS becoming the first funded treatment for a rare bone marrow cancer in a decade - reaching reimbursement just four months after being registered on the ARTG.

GSK's Omjjara is subsidised from 1 April for patients with intermediate or high-risk primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis in patients with moderate to severe anaemia and who are Janus kinase (JAK) inhibitor naive or have been treated with Novartis' Jakavi.

To see the whole article, please login